1 Neuromuscular Blocking Agent (NMBA) Market Overview
1.1 Product Overview and Scope of Neuromuscular Blocking Agent (NMBA)
1.2 Neuromuscular Blocking Agent (NMBA) Segment by Type
1.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Depolarizing
1.2.3 Non-depolarizing
1.3 Neuromuscular Blocking Agent (NMBA) Segment by Application
1.3.1 Global Neuromuscular Blocking Agent (NMBA) Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Pharmacy
1.3.5 Others
1.4 Global Neuromuscular Blocking Agent (NMBA) Market Size Estimates and Forecasts
1.4.1 Global Neuromuscular Blocking Agent (NMBA) Revenue 2017-2028
1.4.2 Global Neuromuscular Blocking Agent (NMBA) Sales 2017-2028
1.4.3 Neuromuscular Blocking Agent (NMBA) Market Size by Region: 2017 Versus 2021 Versus 2028
2 Neuromuscular Blocking Agent (NMBA) Market Competition by Manufacturers
2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturers (2017-2022)
2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Neuromuscular Blocking Agent (NMBA) Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Neuromuscular Blocking Agent (NMBA) Manufacturing Sites, Area Served, Product Type
2.5 Neuromuscular Blocking Agent (NMBA) Market Competitive Situation and Trends
2.5.1 Neuromuscular Blocking Agent (NMBA) Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Neuromuscular Blocking Agent (NMBA) Players Market Share by Revenue
2.5.3 Global Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario by Region
3.1 Global Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.3.1 North America Neuromuscular Blocking Agent (NMBA) Sales by Country
3.3.2 North America Neuromuscular Blocking Agent (NMBA) Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.4.1 Europe Neuromuscular Blocking Agent (NMBA) Sales by Country
3.4.2 Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Region
3.5.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region
3.5.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.6.1 Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country
3.6.2 Latin America Neuromuscular Blocking Agent (NMBA) Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.7.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Country
3.7.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Neuromuscular Blocking Agent (NMBA) Historic Market Analysis by Type
4.1 Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2017-2022)
4.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type (2017-2022)
4.3 Global Neuromuscular Blocking Agent (NMBA) Price by Type (2017-2022)
5 Global Neuromuscular Blocking Agent (NMBA) Historic Market Analysis by Application
5.1 Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2017-2022)
5.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application (2017-2022)
5.3 Global Neuromuscular Blocking Agent (NMBA) Price by Application (2017-2022)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Hengrui Pharmaceutical
6.4.1 Hengrui Pharmaceutical Corporation Information
6.4.2 Hengrui Pharmaceutical Description and Business Overview
6.4.3 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.4.5 Hengrui Pharmaceutical Recent Developments/Updates
6.5 Abbott Laboratories
6.5.1 Abbott Laboratories Corporation Information
6.5.2 Abbott Laboratories Description and Business Overview
6.5.3 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.5.5 Abbott Laboratories Recent Developments/Updates
6.6 Fresenius Kabi
6.6.1 Fresenius Kabi Corporation Information
6.6.2 Fresenius Kabi Description and Business Overview
6.6.3 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.6.5 Fresenius Kabi Recent Developments/Updates
6.7 Sandoz
6.6.1 Sandoz Corporation Information
6.6.2 Sandoz Description and Business Overview
6.6.3 Sandoz Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Sandoz Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.7.5 Sandoz Recent Developments/Updates
6.8 Somerset Therapeutics
6.8.1 Somerset Therapeutics Corporation Information
6.8.2 Somerset Therapeutics Description and Business Overview
6.8.3 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.8.5 Somerset Therapeutics Recent Developments/Updates
6.9 Guike Pharmaceutical
6.9.1 Guike Pharmaceutical Corporation Information
6.9.2 Guike Pharmaceutical Description and Business Overview
6.9.3 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.9.5 Guike Pharmaceutical Recent Developments/Updates
6.10 Shanghai Pharmaceuticals
6.10.1 Shanghai Pharmaceuticals Corporation Information
6.10.2 Shanghai Pharmaceuticals Description and Business Overview
6.10.3 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.10.5 Shanghai Pharmaceuticals Recent Developments/Updates
6.11 Themis Medicare
6.11.1 Themis Medicare Corporation Information
6.11.2 Themis Medicare Neuromuscular Blocking Agent (NMBA) Description and Business Overview
6.11.3 Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Themis Medicare Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.11.5 Themis Medicare Recent Developments/Updates
6.12 Nanjing King-Friend
6.12.1 Nanjing King-Friend Corporation Information
6.12.2 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Description and Business Overview
6.12.3 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.12.5 Nanjing King-Friend Recent Developments/Updates
7 Neuromuscular Blocking Agent (NMBA) Manufacturing Cost Analysis
7.1 Neuromuscular Blocking Agent (NMBA) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Neuromuscular Blocking Agent (NMBA)
7.4 Neuromuscular Blocking Agent (NMBA) Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Neuromuscular Blocking Agent (NMBA) Distributors List
8.3 Neuromuscular Blocking Agent (NMBA) Customers
9 Neuromuscular Blocking Agent (NMBA) Market Dynamics
9.1 Neuromuscular Blocking Agent (NMBA) Industry Trends
9.2 Neuromuscular Blocking Agent (NMBA) Market Drivers
9.3 Neuromuscular Blocking Agent (NMBA) Market Challenges
9.4 Neuromuscular Blocking Agent (NMBA) Market Restraints
10 Global Market Forecast
10.1 Neuromuscular Blocking Agent (NMBA) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Neuromuscular Blocking Agent (NMBA) by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Neuromuscular Blocking Agent (NMBA) by Type (2023-2028)
10.2 Neuromuscular Blocking Agent (NMBA) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Neuromuscular Blocking Agent (NMBA) by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Neuromuscular Blocking Agent (NMBA) by Application (2023-2028)
10.3 Neuromuscular Blocking Agent (NMBA) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Neuromuscular Blocking Agent (NMBA) by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Neuromuscular Blocking Agent (NMBA) by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Comparison by Type (2022-2028) & (MT) & (US$ Million)
Table 2. Global Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Comparison by Application (2022-2028) & (MT) & (US$ Million)
Table 3. Global Neuromuscular Blocking Agent (NMBA) Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Neuromuscular Blocking Agent (NMBA) Market Competitive Situation by Manufacturers in 2021
Table 5. Global Neuromuscular Blocking Agent (NMBA) Sales (MT) of Key Manufacturers (2017-2022)
Table 6. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Neuromuscular Blocking Agent (NMBA) Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Neuromuscular Blocking Agent (NMBA) Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Neuromuscular Blocking Agent (NMBA) Average Price (USD/MT) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Neuromuscular Blocking Agent (NMBA) Manufacturing Sites and Area Served
Table 11. Manufacturers Neuromuscular Blocking Agent (NMBA) Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Neuromuscular Blocking Agent (NMBA) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromuscular Blocking Agent (NMBA) as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Neuromuscular Blocking Agent (NMBA) Sales by Region (2017-2022) & (MT)
Table 16. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2017-2022)
Table 17. Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2017-2022)
Table 19. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2017-2022) & (MT)
Table 20. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2017-2022)
Table 21. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2017-2022)
Table 23. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2017-2022) & (MT)
Table 24. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2017-2022)
Table 25. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2017-2022) & (MT)
Table 28. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2017-2022)
Table 31. Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country (2017-2022) & (MT)
Table 32. Latin America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2017-2022)
Table 33. Latin America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2017-2022) & (MT)
Table 36. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2017-2022)
Table 39. Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2017-2022) & (MT)
Table 40. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2017-2022)
Table 41. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Neuromuscular Blocking Agent (NMBA) Revenue Share by Type (2017-2022)
Table 43. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2017-2022) & (USD/MT)
Table 44. Global Neuromuscular Blocking Agent (NMBA) Sales (MT) by Application (2017-2022)
Table 45. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2017-2022)
Table 46. Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Neuromuscular Blocking Agent (NMBA) Revenue Share by Application (2017-2022)
Table 48. Global Neuromuscular Blocking Agent (NMBA) Price by Application (2017-2022) & (USD/MT)
Table 49. AbbVie Corporation Information
Table 50. AbbVie Description and Business Overview
Table 51. AbbVie Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 52. AbbVie Neuromuscular Blocking Agent (NMBA) Product
Table 53. AbbVie Recent Developments/Updates
Table 54. GlaxoSmithKline Corporation Information
Table 55. GlaxoSmithKline Description and Business Overview
Table 56. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 57. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product
Table 58. GlaxoSmithKline Recent Developments/Updates
Table 59. Pfizer Corporation Information
Table 60. Pfizer Description and Business Overview
Table 61. Pfizer Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 62. Pfizer Neuromuscular Blocking Agent (NMBA) Product
Table 63. Pfizer Recent Developments/Updates
Table 64. Hengrui Pharmaceutical Corporation Information
Table 65. Hengrui Pharmaceutical Description and Business Overview
Table 66. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 67. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product
Table 68. Hengrui Pharmaceutical Recent Developments/Updates
Table 69. Abbott Laboratories Corporation Information
Table 70. Abbott Laboratories Description and Business Overview
Table 71. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 72. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product
Table 73. Abbott Laboratories Recent Developments/Updates
Table 74. Fresenius Kabi Corporation Information
Table 75. Fresenius Kabi Description and Business Overview
Table 76. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 77. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product
Table 78. Fresenius Kabi Recent Developments/Updates
Table 79. Sandoz Corporation Information
Table 80. Sandoz Description and Business Overview
Table 81. Sandoz Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 82. Sandoz Neuromuscular Blocking Agent (NMBA) Product
Table 83. Sandoz Recent Developments/Updates
Table 84. Somerset Therapeutics Corporation Information
Table 85. Somerset Therapeutics Description and Business Overview
Table 86. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 87. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product
Table 88. Somerset Therapeutics Recent Developments/Updates
Table 89. Guike Pharmaceutical Corporation Information
Table 90. Guike Pharmaceutical Description and Business Overview
Table 91. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 92. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product
Table 93. Guike Pharmaceutical Recent Developments/Updates
Table 94. Shanghai Pharmaceuticals Corporation Information
Table 95. Shanghai Pharmaceuticals Description and Business Overview
Table 96. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 97. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product
Table 98. Shanghai Pharmaceuticals Recent Developments/Updates
Table 99. Themis Medicare Corporation Information
Table 100. Themis Medicare Description and Business Overview
Table 101. Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 102. Themis Medicare Neuromuscular Blocking Agent (NMBA) Product
Table 103. Themis Medicare Recent Developments/Updates
Table 104. Nanjing King-Friend Corporation Information
Table 105. Nanjing King-Friend Description and Business Overview
Table 106. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 107. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product
Table 108. Nanjing King-Friend Recent Developments/Updates
Table 109. Production Base and Market Concentration Rate of Raw Material
Table 110. Key Suppliers of Raw Materials
Table 111. Neuromuscular Blocking Agent (NMBA) Distributors List
Table 112. Neuromuscular Blocking Agent (NMBA) Customers List
Table 113. Neuromuscular Blocking Agent (NMBA) Market Trends
Table 114. Neuromuscular Blocking Agent (NMBA) Market Drivers
Table 115. Neuromuscular Blocking Agent (NMBA) Market Challenges
Table 116. Neuromuscular Blocking Agent (NMBA) Market Restraints
Table 117. Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Type (2023-2028) & (MT)
Table 118. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share Forecast by Type (2023-2028)
Table 119. Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 120. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share Forecast by Type (2023-2028)
Table 121. Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Application (2023-2028) & (MT)
Table 122. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share Forecast by Application (2023-2028)
Table 123. Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 124. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share Forecast by Application (2023-2028)
Table 125. Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Region (2023-2028) & (MT)
Table 126. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share Forecast by Region (2023-2028)
Table 127. Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 128. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share Forecast by Region (2023-2028)
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Neuromuscular Blocking Agent (NMBA)
Figure 2. Global Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2021 & 2028
Figure 3. Depolarizing Product Picture
Figure 4. Non-depolarizing Product Picture
Figure 5. Global Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2021 & 2028
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Pharmacy
Figure 9. Others
Figure 10. Global Neuromuscular Blocking Agent (NMBA) Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Neuromuscular Blocking Agent (NMBA) Market Size (2017-2028) & (US$ Million)
Figure 12. Global Neuromuscular Blocking Agent (NMBA) Sales (2017-2028) & (MT)
Figure 13. Neuromuscular Blocking Agent (NMBA) Sales Share by Manufacturers in 2021
Figure 14. Global Neuromuscular Blocking Agent (NMBA) Revenue Share by Manufacturers in 2021
Figure 15. The Global 5 and 10 Largest Neuromuscular Blocking Agent (NMBA) Players: Market Share by Revenue in 2021
Figure 16. Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2017-2022)
Figure 18. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region in 2021
Figure 19. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2017-2022)
Figure 20. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region in 2021
Figure 21. U.S. Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Canada Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Germany Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. France Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. U.K. Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Italy Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Russia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. China Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Japan Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. South Korea Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. India Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Australia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Taiwan Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Indonesia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Thailand Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Malaysia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Philippines Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Vietnam Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Mexico Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Brazil Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Argentina Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Turkey Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Saudi Arabia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. U.A.E Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Sales Market Share of Neuromuscular Blocking Agent (NMBA) by Type (2017-2022)
Figure 46. Manufacturing Cost Structure of Neuromuscular Blocking Agent (NMBA)
Figure 47. Manufacturing Process Analysis of Neuromuscular Blocking Agent (NMBA)
Figure 48. Neuromuscular Blocking Agent (NMBA) Industrial Chain Analysis
Figure 49. Channels of Distribution
Figure 50. Distributors Profiles
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AbbVie GlaxoSmithKline Pfizer Hengrui Pharmaceutical Abbott Laboratories Fresenius Kabi Sandoz Somerset Therapeutics Guike Pharmaceutical Shanghai Pharmaceuticals Themis Medicare Nanjing King-Friend